Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)

Journal of Medicinal Chemistry

Volumn 50, Issue 4, 2007, Pages 765-775

  Sharma, Shailendra Kumar ^a   Parasuraman, Prasanna ^a   Kumar, Gyanendra ^a   Surolia, Namita ^c   Surolia, Avadhesha ^a,b  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^c JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CATECHIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADPH); EPIGALLOCATECHIN GALLATE; FLAVONOID; GREEN TEA EXTRACT; POLYPHENOL DERIVATIVE; TRICLOSAN;

ARTICLE; BINDING AFFINITY; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME KINETICS; MOLECULAR MODEL; NONHUMAN; PLASMODIUM FALCIPARUM; STEADY STATE; TEA;

ANIMALS; ANTIMALARIALS; CATECHIN; CHALCONES; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ESCHERICHIA COLI; KINETICS; MODELS, MOLECULAR; PLASMODIUM FALCIPARUM; PROTEIN BINDING; QUERCETIN; TEA; TRICLOSAN;

EID: 33847401359     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061154d     Document Type: Article

References (48)

1. The World Health Report 1999; WHO: Geneva, pp 49-63.
2. Surolia, N.; Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 2001, 7, 167-173.
3. Wiesner, J.; Seeber, F. The plastid-derived organelle of protozoan human parasites as a target of established and emerging drugs. Expert Opin. Ther. Targets 2005, 9, 23-44.
4. Smith, S.; Witkowski, A.; Joshi, A. K. Structural and functional organization of the animal fatty acid synthase. Prog. Lipid Res. 2003, 42, 289-317.
5. Rock, C. O.; Cronan, J. E. Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. Biochim. Biophys. Acta 1996, 1302, 1-16.
6. Heath, R. J.; Rock, C. O. Fatty acid biosynthesis as a target for novel antibacterials. Curr. Opin. Investig. Drugs 2004, 5, 46-53.
7. Surolia, A.; Ramya, T. N. C.; Ramya, V.; Surolia, N. 'FAS't inhibition of malaria. Biochem. J. 2004, 383, 401-412.
8. Sharma, S. K.; Kapoor, M.; Ramya, T. N. C.; Kumar, G.; Kumar, S.; Modak, R.; Sharma, S.; Surolia, N.; Surolia, A. Identification, characterization, and inhibition of Plasmodium falciparum beta-hydroxyacyl-acyl carrier protein dehydratase [FabZ]. J. Biol. Chem. 2003, 278, 45661-45671.
9. Ralph, S. A.; Van Dooren, G. G.; Waller, R. F.; Crawford, A. F.; Fraunholz, M. J.; Foth, B. J.; Tonkin, C. J.; Roos, D. S.; McFadden, G. I. Metabolic maps and functions of the Plasmodium falciparum apicoplast. Nat. Rev. Microbiol. 2004, 2, 203-216.
10. Waller, R. F.; Reed, M. B.; Cowman, A. F.; McFadden, G. I. Protein trafficking to the plastid of Plasmodium falciparum is via the secretory pathway. EMBO J. 2000, 19, 1794-1802.
11. Heath, R. J.; Rock, C. O. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J. Biol. Chem. 1995, 270, 26538-26542.
12. Zhang, Y. M.; Lu, Y. J.; Rock, C. O. The reductase steps of the type II fatty acid synthase as antimicrobial targets. Lipids 2004, 39, 1055-60.
13. Kapoor, M.; Dar, M. J.; Surolia, A.; Surolia, N. Kinetic determination of the interaction of Enoyl-ACP Reductase from Plasmodium falciparum with its substrates and inhibitors. Biochem. Biophys. Res. Commun. 2001, 289, 832-837.
14. Kapoor, M.; Reddy, C. C.; Krishnasastry, M. V.; Surolia, N.; Surolia, A. Slow-tight-binding inhibition of enoyl-acyl carrier protein reductase from Plasmodium falciparum by triclosan. Biochem. J. 2004, 381, 719-24.
15. +. Biochem. J. 2004, 381, 725-733.
16. Kapoor, M.; Gopalakrishnapai, J.; Surolia, N.; Surolia, A. Mutational analysis of the triclosan-binding region of enoyl-ACP(Acyl Carrier Protein) reductase from Plasmodium falciparum. Biochem. J. 2004, 381, 735-741.
17. Pidugu, L. S.; Kapoor, M.; Surolia, N.; Surolia, A.; Suguna, K. Structural basis for the variation in triclosan affinity to Enoyl Reductases. J. Mol. Biol. 2004, 343, 147-155.
18. Taylor, N. in Green Tea, The Natural Secret for a Healthier Life; Kensington Publishing Corp.: New York, NY, 1998.
19. Cooper, R.; Morré, D. J.; Morré, D. M. Medicinal Benefits of Green Tea: Part II. Review of Anticancer Properties. J. Alternat. Complement. Med. 2005, 11, 639-652.
20. Yang, C. S.; Wang, Z. Y. Tea and Cancer. J. Natl. Cancer Inst. 1993, 85, 1038-1049.
21. Bastianetto, S.; Yao, Z. X.; Papadopoulos, V.; Quirion, R. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur. J. Neurosci. 2006, 23, 55-64.
22. Dorchies, O. M.; Wagner, S.; Vuadens, O.; Waldhauser, K.; Buetler, T. M.; Kucera, P.; Ruegg, U. T. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am. J. Physiol. Cell. Physiol. 2006, 290, 616-25.
23. Cao, Y.; Cao, R. Angiogenesis inhibited by drinking tea. Nature 1999, 398, 381.
24. Yamakawa, S.; Asai, T.; Uchida, T.; Matsukawa, M.; Akizawa, T.; Oku, N. Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis. Cancer Lett. 2004, 210, 47-55.
25. Kitashirakawa, O.; Kyoto, S. Inhibition of human matrix metalloproteinase-7 (MMP-7), an enzyme involved in cancer metastasis, by catechins. Foods Food Ingred. J. Jpn. 2003, 208, 975-979.
26. Tillekeratne, L. M. V.; Sherette, A.; Grossman, P.; Hupe, L.; Hupe, D.; Hudson, R. A. Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2001, 11, 2763-2767.
27. Seeram, N. P.; Zhang, Y.; Nair, M. G. Inhibition of proliferation of human cancer cells and cyclooxygenase enzymes by anthocyanidins and catechins. Nutr. Cancer 2003, 46, 101-106.
28. Naasani, I.; Seimiya, H.; Tsuruo, T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Commun. 1998, 249, 391-396.
29. Seki, A. T.; Noguchi, H.; Kashiwada, Y. Galloyl esters from rhubarb are potent inhibitors of squalene epoxidase, a key enzyme in cholesterol biosynthesis. Planta Med. 2000, 66, 753-756.
30. Wang, X.; Tian, W. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem. Biophys. Res. Commun. 2001, 288, 1200-1206.
31. Li, B. H.; Tian, W. X. Inhibitory effects of flavonoids on animal fatty acid synthase. J. Biochem. 2004, 135, 85-91.
32. Ghosh, K. S.; Maiti, T. S.; Dasgupta, S. Green tea polyphenols as inhibitors of ribonuclease A. Biochem. Biophys. Res. Commun. 2004, 325, 807-811.
33. Zhang, Y. M.; Rock, C. O. Evaluation of epigallocatechin gallate and related plant polyphenols as inhibitors of the FabG and FabI reductases of bacterial type II fatty-acid synthase. J. Biol. Chem. 2004, 279, 30994-1001.
34. Tasdemir, D.; Lack, G.; Burn, R.; Ruedi, P.; Scapozza, L.; Perozzo, R. Inhibition of Plasmodium falciparitm fatty acid biosynthesis: Evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J. Med. Chem. 2006, 49, 3345-3353.
35. i. Biochem. J. 1972, 129, 197-202.
36. Ward, W. H. J.; Holdgate, G. A.; Rowsell, S.; McLean, E. G.; Pauptit, R. A.; Clayton, E.; Nichols, W. W.; Colls, J. G.; Minshull, C. A.; Jude, D. A.; Mistry, A.; Timms, D.; Camble, R.; Hales, N. J.; Britton, C. I.; Taylor, I. W. F. Kinetic and Structural Characteristics of the Inhibition of Enoyl (Acyl Carrier Protein) Reductase by Triclosan. Biochemistry 1999, 38, 12514-12525.
37. Heath, R. J.; Rubin, J. R.; Holland, D. R.; Zhang, E.; Snows, M. E.; Rock, C. O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 1999, 274, 11110-11114.
38. Scatchard, G. The attraction of proteins for small molecules and ions. Ann. N. Y. Acad. Sci. 1949, 51, 660.
39. Morrison, J. F.; Walsh, C. T. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzvmol. Relat. Areas Mol. Biol. 1988, 61, 201-301.
40. Morrison, J. F. The slow binding and slow-tight binding inhibition of enzyme catalyzed reactions. Trends Biochem. Sci. 1982, 7, 102-105.
41. Perozzo, R.; Kuo, M.; Sidhu, A. S.; Valiyaveettil, J. T.; Bittman, R.; Jacobs, W. R., Jr.; Fidock, D. A.; Sacchettini, J. C. Structural Elucidation of the Specificity of the Antibacterial Agent Triclosan for Malarial Enoyl ACP Reductase. J. Biol. Chem. 2002, 277, 13106-13114.
42. McClerren, A. L.; Endsley, S.; Bowman, J. L.; Anderson, N. H.; Guan, Z.; Rudolph, J.; Raetz, C. R. H. A slow, tight-binding inhibitor of the Zinc-dependent deacetylase LpxC of lipid. A biosynthesis with antibiotic activity comparable to Ciprofloxacin. Biochemistry 2005, 44, 16474-16583.
43. Houtzager, V.; Oullet, M.; Flagueyret, J. -P.; Passmore, I. A.; Bayly, C.; Percival, M. D. Inhibitor-induced changes in the intrinsic fluorescence of human cyclooxygenase-2. Biochemistry 1996, 35, 10974-10984.
44. Lakowicz, J. R. Principles of Fluorescence Spectroscopy, Plenum Press: New York, 1983; pp 180-195.
45. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; and Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
46. Molecular Operating Environment [MOE 2001.07], Chemical Computing Group Inc..1255 University St., Suite 1600, Montreal, Quebec, Canada, H3B 3X3.
47. Stewart, M. J.; Parikh, S.; Xiao, G.; Tonge, P. J.; Kisker, C. Structural Basis and Mechanism of Enoyl Reductase Inhibition by Triclosan. J. Mol. Biol. 1999, 290, 859-865.
48. Mehler, E. L.; Solmajer, T. Electrostatic effects in proteins: comparison of dielectric and charge models. Protein Eng. 1991, 4, 903-910.